BCL-2 blockade with Venetoclax enhanced the antilymphoma activity of checkpoint kinase inhibitors in multiple BCL-2 positive cell lines (including ABC and DH DLBCL models) resulting in increased apoptosis (Fig. 4). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.